Significant gene in at least 2 drug CRISPR screens with prognostic significance in all AML pediatric cohorts treated with ADE, irrespective of patients’ risk group
| RNA-seq symbol . | U133A probes . | CRISPR . | Clinically relevant . | AML02 (U133A) . | TARGET-0531 (RNA-seq) . | TARGET-1031 (RNA-seq) . | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AraC . | Dauno . | Etop . | EFS adj . | OS adj . | MRD1 adj . | EFS adj . | OS adj . | MRD1 adj . | EFS adj . | OS adj . | MRD1 adj . | |||
| BCL2 | 207005_s_at_BCL2 | R | R | I | Detrimental | 1.51 (1.06-2.16)∗ | 1.73 (1.11-2.67)∗ | 1.84 (1.07-3.16)∗ | 1.33 (1.02-1.73)∗ | 1.01 (0.75-1.36) | 1.07 (0.69-1.65) | 1.2 (1.01-1.42)∗ | 1.13 (0.92-1.4) | 1.28 (0.93-1.75) |
| CLIP2 | 211031_s_at_CLIP2 | R | R | I | Detrimental | 2.02 (1.36-2.99)∗∗∗ | 2.09 (1.29-3.37)∗∗ | 3.16 (1.68-5.94)∗∗∗ | 0.89 (0.71-1.11) | 0.88 (0.68-1.15) | 1.92 (1.27-2.91)∗∗ | 1.13 (0.99-1.29) | 1.28 (1.08-1.52)∗∗ | 1.53 (1.19-1.97)∗∗∗ |
| VAV3 | 218806_s_at_VAV3 | I | R | R | Detrimental | 1.72 (1.12-2.66)∗ | 2.22 (1.28-3.83)∗∗ | 1.38 (0.81-2.36) | 1.25 (0.95-1.65) | 1.18 (0.85-1.65) | 3.08 (1.69-5.64)∗∗∗ | 1.03 (0.87-1.22) | 1.17 (0.94-1.44) | 2.21 (1.55-3.15)∗∗∗ |
| GRPEL1 | 212434_at_GRPEL1 | S | I | S | Beneficial | 0.6 (0.36-0.98)∗ | 0.44 (0.25-0.76)∗∗ | 0.33 (0.12-0.9)∗ | 1.05 (0.73-1.52) | 1.29 (0.83-1.99) | 0.35 (0.18-0.69)∗∗ | 0.81 (0.64-1.02) | 0.79 (0.59-1.05) | 0.4 (0.26-0.61)∗∗∗ |
| HCFC1 | 202474_s_at_HCFC1 | S | I | S | Beneficial | 0.36 (0.13-0.97)∗ | 0.32 (0.1-1.08) | 0.44 (0.1-1.98) | 0.65 (0.44-0.96)∗ | 0.78 (0.52-1.17) | 1.39 (0.68-2.82) | 0.95 (0.75-1.19) | 0.95 (0.72-1.27) | 0.66 (0.43-1)∗ |
| TAF10 | 200055_at_TAF10 | S | I | S | Beneficial | 0.82 (0.47-1.43) | 0.52 (0.31-0.88)∗ | 0.97 (0.39-2.39) | 1.76 (0.9-3.44) | 1.29 (0.61-2.72) | 0.28 (0.09-0.84)∗ | 0.63 (0.46-0.86)∗∗ | 0.81 (0.55-1.2) | 0.52 (0.29-0.94)∗ |
| RNA-seq symbol . | U133A probes . | CRISPR . | Clinically relevant . | AML02 (U133A) . | TARGET-0531 (RNA-seq) . | TARGET-1031 (RNA-seq) . | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AraC . | Dauno . | Etop . | EFS adj . | OS adj . | MRD1 adj . | EFS adj . | OS adj . | MRD1 adj . | EFS adj . | OS adj . | MRD1 adj . | |||
| BCL2 | 207005_s_at_BCL2 | R | R | I | Detrimental | 1.51 (1.06-2.16)∗ | 1.73 (1.11-2.67)∗ | 1.84 (1.07-3.16)∗ | 1.33 (1.02-1.73)∗ | 1.01 (0.75-1.36) | 1.07 (0.69-1.65) | 1.2 (1.01-1.42)∗ | 1.13 (0.92-1.4) | 1.28 (0.93-1.75) |
| CLIP2 | 211031_s_at_CLIP2 | R | R | I | Detrimental | 2.02 (1.36-2.99)∗∗∗ | 2.09 (1.29-3.37)∗∗ | 3.16 (1.68-5.94)∗∗∗ | 0.89 (0.71-1.11) | 0.88 (0.68-1.15) | 1.92 (1.27-2.91)∗∗ | 1.13 (0.99-1.29) | 1.28 (1.08-1.52)∗∗ | 1.53 (1.19-1.97)∗∗∗ |
| VAV3 | 218806_s_at_VAV3 | I | R | R | Detrimental | 1.72 (1.12-2.66)∗ | 2.22 (1.28-3.83)∗∗ | 1.38 (0.81-2.36) | 1.25 (0.95-1.65) | 1.18 (0.85-1.65) | 3.08 (1.69-5.64)∗∗∗ | 1.03 (0.87-1.22) | 1.17 (0.94-1.44) | 2.21 (1.55-3.15)∗∗∗ |
| GRPEL1 | 212434_at_GRPEL1 | S | I | S | Beneficial | 0.6 (0.36-0.98)∗ | 0.44 (0.25-0.76)∗∗ | 0.33 (0.12-0.9)∗ | 1.05 (0.73-1.52) | 1.29 (0.83-1.99) | 0.35 (0.18-0.69)∗∗ | 0.81 (0.64-1.02) | 0.79 (0.59-1.05) | 0.4 (0.26-0.61)∗∗∗ |
| HCFC1 | 202474_s_at_HCFC1 | S | I | S | Beneficial | 0.36 (0.13-0.97)∗ | 0.32 (0.1-1.08) | 0.44 (0.1-1.98) | 0.65 (0.44-0.96)∗ | 0.78 (0.52-1.17) | 1.39 (0.68-2.82) | 0.95 (0.75-1.19) | 0.95 (0.72-1.27) | 0.66 (0.43-1)∗ |
| TAF10 | 200055_at_TAF10 | S | I | S | Beneficial | 0.82 (0.47-1.43) | 0.52 (0.31-0.88)∗ | 0.97 (0.39-2.39) | 1.76 (0.9-3.44) | 1.29 (0.61-2.72) | 0.28 (0.09-0.84)∗ | 0.63 (0.46-0.86)∗∗ | 0.81 (0.55-1.2) | 0.52 (0.29-0.94)∗ |
∗, ∗∗, and ∗∗∗ indicate significant terms at the P < .05; P < .01; and P < .001 statistical levels, respectively. Boldface values indicate significant results.
adj, risk adjusted; Dauno, daunorubicin; Etop, etoposide; I, inert; R, resistant; RNA-seq, RNA sequencing; S, sensitive.